🇨🇩 EVD Survivor Program in DRC
F Tshimanga Kazadi, L Fontana, A Legand and A Chaillon
2025-03-18
At a glance
- This dataset include 1139 unique individuals.
- Participants underwent a mean of 17.94 visits (min=1, max=44).
- Participants were followed for a mean duration of 2.14 years (min=0.03, max=4.52).
Overview
Population characteristics
Characteristic |
N = 1,139 1 |
|---|---|
| Sex | |
| Female | 627 (55%) |
| Male | 512 (45%) |
| Age | 29 (1, 81) |
| Age group | |
| ≤5 yrs | 61 (5.4%) |
| 5-15 yrs | 135 (12%) |
| 15-25 yrs | 281 (25%) |
| 25-45 yrs | 457 (40%) |
| 45-65 yrs | 177 (16%) |
| >65 yrs | 24 (2.1%) |
| occupation | |
| Agriculteur | 315 (30%) |
| Autre | 115 (11%) |
| Enfant | 183 (18%) |
| Étudiant | 45 (4.3%) |
| Femme au foyer | 208 (20%) |
| Fonctionnaire d'Etat | 14 (1.3%) |
| Minier | 18 (1.7%) |
| Personne d'affaire | 44 (4.2%) |
| Professeur/Universitaire | 10 (1.0%) |
| Professionnel de santé | 89 (8.5%) |
| nombre de visites | 1.00 (1.00, 37.00) |
| nombre de visites psychologiques | 1.00 (1.00, 18.00) |
| 1
n (%); Median (Min, Max) |
|
- 31 (N=1475) participants were followed for at least 24 months.
- Mean of 17.9 (median:19; 95%CI:17.6-18.3) visits per participant.
- Mean of 2.1 years (median:1.9; 95%CI:2.1-2.2) of follow up duration.
Comorbidities and complications
Technical note
Missingness
- At 6 months (N = 1110)
- At 12 months (N = 1118)
- At 18 months (N = 1144)
- At 24 months (N = 871)
- At 36 months (N = 191)
- Percentage of missingness. for variable with ≥1% missing is presented.
Approaches for missingness
scenarios
- For the downstream analyses, we proposed the second scenario
Clinical evaluation
Trends
| labels | 6 months | 12 months | 18 months | 24 months | 36 months | Average | Improvement |
|---|---|---|---|---|---|---|---|
| Sensation grattage | 6.43 | 0.00 | 0.00 | 0.00 | 15.18 | 4.32 | -136.08 |
| Murmures vesiculaires | 65.62 | 70.89 | 63.86 | 60.71 | 42.41 | 60.70 | 35.37 |
| Troubles sensitifs | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 100 |
| Troubles equilibre coordination mouvements | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 80.00 | 100 |
| Troubies sommeil | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0 |
| Trouble langage | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 100 |
| Flou visuel | 0.00 | 0.00 | 0.00 | 0.00 | 7.85 | 1.57 | -Inf |
| Abdomen sensible | 0.00 | 0.00 | 0.00 | 0.00 | 6.81 | 1.36 | -Inf |
Clinical evolution of signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.
Clinical evaluation at baseline
Baseline evaluation of signs with a minimum prevalence of 10 cases.
Baseline evaluation of signs with a minimum frequency of 5%.
Clinical presentation over time
Clinical presentation within the first 9 months
Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.
Clinical presentation within the first 3 years
Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.
Psychological evaluation
Within the first 3 months
Quality of life (QALY)
QALY
Day by day prevalence trends
Disease burden
Disease burden
Thank you
Any questions or suggestions? Contact us: Anaïs Legand, Luca Fontana and Antoine Chaillon
EVD survivor program